PFCS
KZR

Pale Fire Capital SE’s Kezar Life Sciences KZR Stock Holding History

Pale Fire Capital SE’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,885
Closed -$65.2K – 67
2023
Q4 		$65.2K Hold
6,885
– – 0.01% 68
2023
Q3 		$81.9K Buy
+6,885
New +$122K 0.01% 60

Other funds holding KZR

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pale Fire Capital SE's KZR Position: Q1 2024 in Review

Pale Fire Capital SE sold out of Kezar Life Sciences (KZR) in Q1 2024, closing a stake of 6,885 shares — an estimated $65.2K sold.

Pale Fire Capital SE first reported a position in KZR in Q3 2023 and held it in 2 quarters. The position peaked at $81.9K in Q3 2023. 85 funds tracked by Wall St. Rank hold KZR as of Q1 2024.

  • Pale Fire Capital SE reported no remaining Kezar Life Sciences position as of Q1 2024 after selling out during the quarter.
  • Pale Fire Capital SE sold 6,885 Kezar Life Sciences shares in Q1 2024, an estimated $65.2K.
  • Pale Fire Capital SE first reported a position in Kezar Life Sciences in Q3 2023 and held it in 2 quarters.
  • Pale Fire Capital SE's Kezar Life Sciences position peaked at $81.9K in Q3 2023.
  • 85 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2024.

Based on Pale Fire Capital SE's 13F filing for Q1 2024, filed 14 May 2024.